NKTRNasdaqPharmaceutical PreparationsFiscal year ends December 31
NEKTAR THERAPEUTICS
Financials through Q4 FY2025, quarter ended Dec 31, 2025Last filing: 10-Q on Aug 14, 2026
$36.64+0.86 (+2.40%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Nektar Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Nektar Therapeutics | Industry median |
|---|---|---|
| Market Cap | $1.25B | $164.85M |
| Enterprise Value | $566.66M | $87.06M |
| PS Ratio | 22.65 | 3.60 |
| PB Ratio | 1.39 | 2.03 |
| P/TBV Ratio | 1.39 | 2.31 |
Enterprise value
| Measure | Nektar Therapeutics | Industry median |
|---|---|---|
| EV / Sales | 10.26 | 2.43 |
Income (trailing twelve months)
| Measure | Nektar Therapeutics | Industry median |
|---|---|---|
| Revenue | $55.23M | $57.94M |
| Gross Profit | $55.23M | $90.47M |
| Operating Income | -$140.10M | -$21.44M |
| Pretax Income | -$164.21M | -$14.45M |
| Net Income | -$164.08M | -$22.46M |
| EBITDA | -$139.08M | -$16.91M |
| EPS (Diluted) | -$9.73 | -$0.83 |
Margins
| Measure | Nektar Therapeutics | Industry median |
|---|---|---|
| Gross Margin | 100.0% | 52.3% |
| Operating Margin | -253.7% | -44.5% |
| Pretax Margin | -297.3% | -13.0% |
| Profit Margin | -297.1% | -39.2% |
| EBITDA Margin | -251.8% | -31.3% |
| FCF Margin | -377.8% | -8.85% |
Returns
| Measure | Nektar Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -37.3% | -53.1% |
| Return on Assets (ROA) | -25.2% | -41.0% |
| Return on Invested Capital (ROIC) | -1185.9% | -32.0% |
| Return on Capital Employed (ROCE) | -13.7% | -37.8% |
Growth
| Measure | Nektar Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -43.9% | 6.01% |
| Revenue Growth (3Y CAGR) | -15.7% | 2.25% |
| Revenue Growth (5Y CAGR) | -18.4% | 6.42% |
Balance sheet
| Measure | Nektar Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $684.34M | $62.42M |
| Net Cash (Debt) | $684.34M | $15.68M |
| Net Cash Per Share | $20.04 | $0.66 |
| Equity (Book Value) | $903.12M | $48.79M |
| Book Value Per Share | $26.45 | $1.36 |
| Tangible Book Value | $903.12M | $23.06M |
| Working Capital | $668.42M | $75.77M |
Financial position
| Measure | Nektar Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 10.42 | 3.30 |
| Quick Ratio | 9.64 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Nektar Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$208.51M | -$12.35M |
| Capital Expenditures | -$171.00K | -$1.06M |
| Free Cash Flow | -$208.68M | -$20.28M |
| FCF Per Share | -$6.11 | -$0.42 |
Efficiency
| Measure | Nektar Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.08 | 0.38 |
| Revenue Per Employee | $876.70K | $398.96K |
| Profits Per Employee | -$2.60M | -$703.34K |
| Employee Count | 63 | 74 |
Dividends and yields
| Measure | Nektar Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -13.1% | -22.7% |
| FCF Yield | -16.7% | -9.07% |
| Buyback Yield | 0.00% | -0.73% |
| Shareholder Yield | 0.00% | 0.00% |
Shares
| Measure | Nektar Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 34,143,000 | 58,179,650 |
| Shares Change (YoY) | 23.0% | 11.1% |
| Float | 33,986,300 | 49,173,100 |
| Shares Held by Insiders | 0.46% | 11.6% |
| Shares Held by Institutions | 105.2% | 59.4% |
Taxes
| Measure | Nektar Therapeutics | Industry median |
|---|---|---|
| Income Tax | -$138.00K | $91.50K |
Scores
| Measure | Nektar Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -0.65 | -0.24 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Nektar Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.